RxDoctor Payments Data

Andrew McWhorter, MD

Otolaryngology · Baton Rouge, LANPI 1376524918

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $8,750 of the $11,649 with a category attached, or 75.1%. Lumenis, Inc accounts for 75.1% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2020 at $5,000 and has fallen 92.2% since, to $392 in 2025. Among otolaryngology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,649in general payments, 2019–2025

Across 30 payments — averaging $388.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lumenis, Inc$9K
  • Boston Scientific$1K
  • Medtronic$388
  • Olympus America Inc.$197
  • Integra Lifesciences Corporation$195
  • Grace Medical, Inc.$186
  • plus $619 from 7 others

What the payments were for

  • Consulting fees$1,20010%
  • Speaking & faculty fees$8,75075%
  • Food & beverage$1,69915%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,649 in reported general payments places this provider in the 90th percentile of 218 otolaryngology providers in Louisiana.

See all otolaryngology providers in Louisiana

Medicare billing

Part B allowed, 2024
$113,042
Medicare patients
281
Services billed
1,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Arnuity ElliptaFluticasone Furoate14$2,868
Clotrimazole58$1,641
Azithromycin47$555
Gabapentin12$94
Amoxicillin20$50
Pantoprazole Sodium15$45

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArnuity Ellipta$100$2,86814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 218 otolaryngology providers in Louisiana.

Other otolaryngology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →